Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.40 USD
Change Today -0.13 / -1.23%
Volume 3.3M
IRWD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

ironwood pharmaceuticals inc (IRWD) Snapshot

Open
$10.53
Previous Close
$10.53
Day High
$10.60
Day Low
$10.20
52 Week High
01/27/15 - $17.11
52 Week Low
07/27/15 - $10.19
Market Cap
1.5B
Average Volume 10 Days
1.9M
EPS TTM
$-1.25
Shares Outstanding
125.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IRONWOOD PHARMACEUTICALS INC (IRWD)

ironwood pharmaceuticals inc (IRWD) Related Businessweek News

No Related Businessweek News Found

ironwood pharmaceuticals inc (IRWD) Details

Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union. It has collaboration agreements with Actavis plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, as well as in China, Hong Kong, and Macau. The company also has license agreements with Almirall, S.A. and Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Europe, as well as Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

464 Employees
Last Reported Date: 02/18/15
Founded in 1998

ironwood pharmaceuticals inc (IRWD) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $100.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $331.3K
Chief Scientific Officer, Senior Vice Preside...
Total Annual Compensation: $388.1K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $377.6K
Chief Legal Officer, Senior Vice President an...
Total Annual Compensation: $371.0K
Compensation as of Fiscal Year 2014.

ironwood pharmaceuticals inc (IRWD) Key Developments

Ironwood Pharmaceuticals, Inc. Progresses sGC Stimulator Platform with Positive Top-Line Phase I Data on IW-1973

Ironwood Pharmaceuticals, Inc. announced positive top-line data from a Phase I study of IW-1973, its lead investigational soluble guanylate cyclase (sGC) stimulator. In the study, IW-1973 demonstrated cardiovascular pharmacodynamic effects, extensive tissue distribution, proof of mechanism for sGC stimulation, and a dose range that was well tolerated in healthy volunteers. The totality of clinical and preclinical data generated to date strongly support continued development of IW-1973 as a potential once-daily oral therapy. Ironwood intends to initiate a Phase Ib multiple ascending dose study of IW-1973 in the fourth quarter of 2015. This study will inform the selection of doses and priority indications for the Phase II program, which will focus on areas with the unmet need and optimal path to market. Ironwood intends to initiate at least two Phase II proof of concept studies for IW-1973 in 2016. The randomized, double-blind, placebo-controlled, single ascending dose Phase I study enrolled 46 healthy volunteers. Participants were randomized 3:1 to receive a single dose of IW-1973 or placebo administered via an oral capsule. Top-line clinical data were consistent with preclinical findings and included cardiovascular pharmacodynamic effects, dose-proportional pharmacokinetics, biomarker-based confirmation of target engagement, and evidence of extensive distribution to tissues. No serious adverse events were reported. Reported adverse events were consistent with the mechanism of action. Data from clinical and preclinical studies of IW-1973 are expected to be presented at a future medical conference.

AstraZeneca Pharmaceuticals Co., Ltd. and Ironwood Pharmaceuticals, Inc. Reports Positive Top-Line Data from Phase III IBS-C Trial Designed to Support Linaclotide Approval in China

AstraZeneca Pharmaceuticals Co., Ltd. and Ironwood Pharmaceuticals, Inc. announced that top-line data demonstrate linaclotide met all primary and secondary endpoints, covering multiple abdominal and constipation symptoms, in a Phase III clinical trial of adults with irritable bowel syndrome with constipation (IBS-C). The trial was conducted primarily in China and the companies intend to file in early 2016 for China Food and Drug Administration (CFDA) approval to market linaclotide. Linaclotide is currently approved in the United States for the treatment of adults with IBS-C or chronic idiopathic constipation (CIC) and in a number of other countries for adults with IBS-C. Top-line data from the Phase III trial indicate linaclotide-treated patients showed statistically significant improvement compared to placebo-treated patients for both co-primary endpoints. 60.0% of linaclotide-treated patients were Abdominal Pain/Discomfort Responders, compared to 48.8% of placebo-treated patients (p=0.001). 31.7% of linaclotide-treated patients were IBS Degree of Relief Responders, compared to 15.4% of placebo-treated patients ($125 million in additional commercial milestone payments from AstraZeneca contingent on the achievement of certain sales targets.

Ironwood Pharmaceuticals Seeks Acquisitions

Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD) announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2022. Ironwood intends to use the net proceeds of the offering to strengthen its balance sheet, improve its capital structure and the acquisition of, or investment in, businesses or other strategic assets, and to pay the cost of the convertible note hedge transactions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRWD:US $10.40 USD -0.13

IRWD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $6.12 USD -0.05
Nektar Therapeutics $12.17 USD -0.71
Progenics Pharmaceuticals Inc $8.43 USD -0.99
Sucampo Pharmaceuticals Inc $21.39 USD -1.32
Theravance Inc $15.62 USD -0.37
View Industry Companies
 

Industry Analysis

IRWD

Industry Average

Valuation IRWD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.4x
Price/Book 21.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRONWOOD PHARMACEUTICALS INC, please visit www.ironwoodpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.